Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

56.64USD
23 Jun 2017
Change (% chg)

$-0.69 (-1.20%)
Prev Close
$57.33
Open
$57.27
Day's High
$57.36
Day's Low
$56.24
Volume
20,798,924
Avg. Vol
9,502,556
52-wk High
$77.12
52-wk Low
$46.01

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb announces expiration of cash tender offer
Wednesday, 21 Jun 2017 06:59am EDT 

June 21 (Reuters) - Bristol-Myers Squibb Co ::Bristol-Myers Squibb announces the expiration of its cash tender offer.Bristol-Myers Squibb announces the expiration of its cash tender offer.Bristol-Myers -approximately $337.0 million in aggregate principal amount of notes subject to tender offer were validly tendered and not validly withdrawn.  Full Article

Bristol-Myers announces results from extended follow-up data evaluating opdivo
Friday, 16 Jun 2017 06:58am EDT 

June 16 (Reuters) - Bristol-Myers Squibb Co ::Extended follow-up data evaluating opdivo (nivolumab) shows durable response in adult patients with relapsed or progressed classical hodgkin lymphoma.Bristol-Myers Squibb- ‍results show overall response rates of 65%/greater with median follow-up of at least 16 months.Bristol-Myers says as per extended follow-up data evaluating opdivo​, ‍across cohorts, median overall survival not reached, 40% of patients remained on treatment.  Full Article

Bristol-Myers Squibb to sell manufacturing facility to SK Biotek Co
Friday, 16 Jun 2017 04:35am EDT 

June 16 (Reuters) - Bristol-Myers Squibb Co : :Bristol-Myers Squibb to sell manufacturing facility in swords, Ireland to SK Biotek Co., Ltd..Bristol-Myers - to sell small molecule active pharmaceutical ingredient manufacturing facility in swords, Ireland, to SK Biotek.Bristol-Myers Squibb Co - transaction has been approved by boards of directors of both companies.  Full Article

Bristol-Myers Squibb announces cash tender offer
Wednesday, 14 Jun 2017 08:40am EDT 

June 14 (Reuters) - Bristol-myers Squibb Co :Announces cash tender offer for any and all of certain of its outstanding debt securities.Commenced a cash tender offer for any and all of its 5.875 pct notes due 2036, 6.125 pct notes due 2038 and 6.875 pct debentures due 2097.Expiration date of tender offer is 5:00 p.m., New York City time, on June 20, 2017.  Full Article

Bristol-Myers Squibb declares quarterly dividend of $0.39/shr
Tuesday, 13 Jun 2017 04:05pm EDT 

June 13 (Reuters) - Bristol-myers Squibb Co ::Bristol-Myers Squibb Co says declared a quarterly dividend of $0.39 per share on $.10 par value common stock of corporation.  Full Article

Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer
Monday, 5 Jun 2017 04:05pm EDT 

June 5 (Reuters) - Bristol-myers Squibb Co :Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer.Entered into a clinical research collaboration with Novartis.  Full Article

Incyte says epacadostat, Bristol-Myers' Opdivo combo data positive in head and neck cancer patients
Monday, 5 Jun 2017 07:30am EDT 

June 5 (Reuters) - Incyte Corp :Clinical trial data for combination of epacadostat and opdivo® (nivolumab) demonstrate durable clinical responses in patients with melanoma and head and neck cancer.Incyte corp - combination of ido1 enzyme inhibition plus opdivo was generally well-tolerated in patients with select advanced solid tumors.  Full Article

European commission approves Bristol-Myers Squibb’s opdivo (nivolumab)
Friday, 2 Jun 2017 05:00pm EDT 

June 2 (Reuters) - Bristol-Myers Squibb Co ::European Commission approves Bristol-Myers Squibb’s opdivo (nivolumab) for previously treated locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.Bristol-Myers Squibb Co - ‍opdivo is now approved in european union for eight indications in six distinct tumor types​.  Full Article

Bristol-Myers announces first disclosure of data from a cohort of phase 1/2 CheckMate-358 study
Friday, 2 Jun 2017 06:59am EDT 

June 2 (Reuters) - Bristol-myers Squibb Co :Bristol-Myers - Announces first disclosure of data from a cohort of phase 1/2 CheckMate -358 study.Bristol-Myers Squibb Co says median duration of response has not been reached after 6 months of follow-up.Bristol-Myers Squibb Co - Grade 3/4 treatment-related adverse events occurred in 12.5% of patients in phase 1/2 checkmate -358 study evaluating Opdivo.Bristol-Myers - Opdivo showed safety profile consistent with previous results seen with Opdivo monotherapy in other tumor types, in CheckMate -358​ study.Bristol-Myers - ‍overall response rate of 26.3% in patients with cervical cancer regardless of PD-l1, HPV status and number of prior systemic therapies​.  Full Article

Bristol-Myers Squibb and Seattle Genetics expand collaboration to evaluate combination of opdivo and adcetris
Friday, 2 Jun 2017 06:00am EDT 

June 2 (Reuters) - Bristol-myers Squibb Co :Bristol-Myers Squibb and Seattle Genetics expand clinical collaboration to evaluate combination of opdivo (nivolumab) and adcetris® (brentuximab vedotin) in pivotal phase 3 clinical trial in relapsed hodgkin lymphoma.Bristol-Myers Squibb Co - ‍pivotal phase 3 trial planned for mid-2017​.Bristol-Myers - phase 3 trial to evaluate adcetris alone or with opdivo in relapsed/refractory or transplant-ineligible advanced classical hodgkin lymphoma.Bristol-Myers Squibb- in addition to planned trial, adcetris, opdivo being evaluated as combination therapy in multiple ongoing phase 1/2 clinical trials.Bristol-Myers Squibb Co -adcetris, opdivo combination being evaluated for older hl patients,relapsed/refractory classical hl for children, adolescents.  Full Article

More From Around the Web

U.S. Supreme Court ruling threatens massive talc litigation against J&J

June 21 Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.